FindTrial
Sign In

Does MIBI scan differentiate benign from malignant kidney mass

Prospective evaluation of Tc 99m Sesta MIBI scan to differentiate benign solid renal mass from more aggressive malignant RCC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/05/033661
Enrollment
60
Registered
2021-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis

Interventions

None listed

Sponsors

AIIMS Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients with solid renal mass on imaging 2)Normal preoperative renal function tests

Exclusion criteria

Exclusion criteria: Patient not giving consent Patients with previous history of renal surgery

Design outcomes

Primary

MeasureTime frame
1) To evaluate the role of Tc 99m Sesta MIBI scan to differentiate the benign solid renal mass from aggressive malignant Renal cell carcinoma and correlate with the histopathological stage. Timepoint: 1 year—

Secondary

MeasureTime frame
1) To look whether Tc 99m Sesta MIBI scan helps in decision making and management of patient with RCC. 2)To assess the validity of Tc 99m Sesta MIBI scan in solid renal mass and standardised the protocol.Timepoint: 1 year—

Countries

India

Contacts

Public ContactDr Manoj Kumar

All India Institute of Medical Sciences, AIIMS, Delhi

drmanoj1611@yahoo.com9871195787

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026